^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PVRIG inhibitor

    Related drugs:
    1m
    First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=158, Recruiting, GlaxoSmithKline | Trial completion date: Sep 2028 --> Aug 2027 | Trial primary completion date: Sep 2028 --> Aug 2027
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608) • risvutatug rezetecan (GSK5764227)
    4ms
    Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=408, Active, not recruiting, Jiangsu Simcere Pharmaceutical Co., Ltd. | Not yet recruiting --> Active, not recruiting | N=68 --> 408 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab)
    5ms
    A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Compugen Ltd | Initiation date: Apr 2025 --> Jul 2025
    Trial initiation date • Platinum sensitive
    |
    COM701
    8ms
    A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=60, Recruiting, Compugen Ltd | Not yet recruiting --> Recruiting
    Enrollment open • Platinum sensitive
    |
    COM701
    9ms
    A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=60, Not yet recruiting, Compugen Ltd
    New P1/2 trial
    |
    COM701
    12ms
    The inhibitory receptor PVRIG is dominantly expressed in the bone marrow of patients with multiple myeloma and its blockade enhances T-cell engager's immune activation. (PubMed, Exp Hematol)
    Beyond TIGIT, the DNAM-1 axis includes the novel inhibitory receptor PVRIG. In this study we evaluated the expression of DNAM-1 axis receptors and the function of PVRIG in bone marrow of individuals with MM, specifically highlighting PVRIG blockade as a potential therapeutic opportunity in combination with bi-specific T-cell engager (BiTE).
    Journal • IO biomarker
    |
    TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    1year
    CD34+ and CD34- MM cells show different immune-checkpoint molecule expression profiles: high expression of CD112 and CD137 ligand on CD34+ MM cells. (PubMed, Int J Hematol)
    In addition, CD4+ and CD8+ T cells more frequently expressed TIGIT and CD137, suggesting that CD112/TIGIT and CD137L/CD137 interactions may suppress T-cell activity against CD34+ MM cells. Furthermore, our finding of higher FcRH5 expression on CD34+ MM cells is encouraging for future research into the efficacy of FcRH5-targeted therapy in MM.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • CD70 (CD70 Molecule) • CD34 (CD34 molecule) • TNFRSF9 (TNF Receptor Superfamily Member 9) • TNFRSF14 (TNF Receptor Superfamily Member 14) • ICOSLG (Inducible T Cell Costimulator Ligand) • NECTIN2 (Nectin Cell Adhesion Molecule 2)
    |
    TIGIT expression
    1year
    First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=141, Recruiting, GlaxoSmithKline | Trial completion date: Oct 2026 --> Sep 2028 | Trial primary completion date: Oct 2026 --> Sep 2028
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Jemperli (dostarlimab-gxly) • belrestotug (EOS-448) • nelistotug (GSK6097608) • risvutatug rezetecan (GSK5764227)
    over1year
    A Clinical Trial to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC (clinicaltrials.gov)
    P1/2, N=140, Not yet recruiting, Biotheus Inc.
    New P1/2 trial • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • pumitamig (BNT327)
    over1year
    COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1/2, N=48, Completed, Compugen Ltd | Active, not recruiting --> Completed | N=100 --> 48
    Trial completion • Enrollment change • Combination therapy • Metastases
    |
    TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701 • renvistobart (BMS-986207)
    over1year
    COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=121, Completed, Compugen Ltd | Active, not recruiting --> Completed | Trial completion date: May 2024 --> Jan 2024
    Trial completion • Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset) • TNFRSF9 (TNF Receptor Superfamily Member 9)
    |
    Opdivo (nivolumab) • COM701
    over1year
    A phase II study of SHR-2002 combined with Adebrelimab and Docetaxel in Advanced Non-small-cell lung Cancer (NSCLC) with negative driver genes previously treated with immunosuppressive agents and platinum-based doublet-chemotherapy (ChiCTR2400086491)
    P2, N=16, Not yet recruiting, Fujian Cancer Hospital; Fujian Cancer Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    docetaxel • AiRuiLi (adebrelimab)